PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents yoy growth below half of TRVN's 140.60%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
-100.00%
Both TRVN and the company show zero Short-Term Investments Growth.
6.22%
Below half of TRVN's 140.60%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of TRVN's 69.83%. David Dodd sees a leaner approach to short-term items.
13.80%
Below half of TRVN's 125.99%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
2.11%
Below half TRVN's -24.83%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Below half of TRVN's -11.80%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Below half of TRVN's 124.46%. Michael Burry sees a potential red flag for stagnation or capital shortage.
62.36%
Less than half of TRVN's 465.82%. David Dodd sees a more disciplined AP approach or lower volume.
-40.14%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
133.46%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
184.58%
Less than half of TRVN's -96.11%. David Dodd sees fewer expansions in other current obligations.
173.41%
Above 1.5x TRVN's 78.82%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Above 1.5x TRVN's 56.05%. Michael Burry sees a potential leverage warning sign.
4.06%
Less than half of TRVN's 2638.31%. David Dodd sees fewer share issuances vs. competitor.
-25.11%
≥ 1.5x TRVN's -11.39%. David Dodd sees higher yoy retained profits than competitor.
-90.06%
Less than half of TRVN's -2319.75%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRVN's zero value, indicating worse performance.
-763.59%
Below half TRVN's 130.43%. Michael Burry sees potential underperformance in building shareholder capital.
13.78%
Below half TRVN's 124.46%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both TRVN and the company show zero Total Investments Growth.
-40.14%
Higher Total Debt Growth compared to TRVN's zero value, indicating worse performance.
-7.59%
Less than half of TRVN's -140.60%. David Dodd sees better deleveraging or stronger cash buildup than competitor.